Posts by: Alice Melão

News

Renflexis (infliximab-abda), Merck’s biosimilar of Remicade (infliximab), has been added to the public drug plan of the Canadian province of British Columbia. As of Aug. 21, adults and children with Crohn’s ... Read more

July 30, 2018July 30, 2018

Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar

News

Qu Biologics has started enrolling patients in the RESTORE Phase 2 trial to evaluate its lead investigative immunotherapy, QBECO SSI, in patients with moderate to severe Crohn’s disease. The study ... Read more

March 26, 2018March 26, 2018

Investigational Therapy RHB-107 Holds Potential to Treat IBD, Other Disorders, RedHill Announces

News

RedHill Biopharma is evaluating the potential of its proprietary therapy RHB-107 (upamostat, formerly known as Mesupron) to treat inflammatory digestive diseases and cancer, the company announced in a press release. Results ... Read more

January 19, 2018January 19, 2018

Vitality Biopharma Seeks FDA’s Orphan Drug Status for Cannabinoid Therapy VITA-100

News

Vitality Biopharma is seeking orphan drug designation from the U.S. Food and Drug Administration (FDA) for its targeted cannabinoid therapy, VITA-100, for the treatment of pediatric ulcerative colitis. The FDA grants orphan ... Read more

January 17, 2018

FDA to Review Sandoz’s Application for Biosimilar to Bowel Disease Therapy Humira

News

The U.S. Food and Drug Administration has agreed to review Sandoz’s application for a biosimilar to AbbVie’s bowel disease therapy Humira (adalimumab). “When patients are dealing with a chronic disease, it is imperative ... Read more

January 16, 2018January 16, 2018

LRRK2 Gene May Link Crohn’s and Parkinson’s Among Ashkenazi Jews, Study Finds

News

Ashkenazi Jews with Crohn’s disease are more likely to have mutations on the LRRK2 gene — a known cause of inherited Parkinson’s disease — say researchers with the Icahn School of Medicine at ... Read more

January 10, 2018January 10, 2018

Phase 1 Results Support Development of TopiVert Therapy for Ulcerative Colitis

News

Positive safety data from a Phase 1 trial supports TopiVert’s continued development of TOP1288 to treat ulcerative colitis, the British pharma company announced. TOP1288 targets several important enzymes including P38, Src, Lck and ... Read more

December 21, 2017

Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies

News

Boehringer Ingelheim and Roche are teaming up to develop a new class of inflammatory bowel diseases treatments. The partners will be focusing on therapies based on an innovative approach called Locked Nucleic ... Read more

December 13, 2017December 13, 2017

Protein Secreted by Parasitic Worms May Treat IBD by Easing Gut Inflammation, Study Reports

News

A protein secreted by parasitic worms can block immune cells from promoting inflammation, a finding of possible therapeutic value for such inflammatory bowel diseases (IBD) as Crohn’s and ulcerative colitis. The study by ... Read more

November 6, 2017November 6, 2017

Real-world Data Continues Showing Benefits of Takeda’s Entyvio for IBD Patients

News

Real-world data demonstrates the safety, tolerability, and efficacy of Entyvio (vedolizumab) in treating ulcerative colitis (UC) and Crohn’s disease, confirming previous data collected in clinical trials. These findings were the ... Read more